RxDoctor Payments Data

Pamela Weinhold, MD

Internal Medicine · Shawnee, KSNPI 1467495366

Payments from drug & device makers

$298in general payments, 2019–2025

Across 17 payments — averaging $17.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$106
  • Dexcom, Inc.$77
  • AbbVie$39
  • GSK$30
  • E.r. Squibb & Sons, L.L.C.$19
  • Novo Nordisk$15
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$298100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen6$106
Dexcom, Inc.4$77
AbbVie2$39
GSK2$30
E.r. Squibb & Sons, L.L.C.1$19
Novo Nordisk1$15
Bayer1$12

How this compares

$298 in reported general payments places this provider in the 60th percentile of 705 internal medicine providers in Kansas.

See all internal medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$66,951
Medicare patients
483
Services billed
1,383

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide168$182,879
EliquisApixaban196$174,906
JardianceEmpagliflozin96$96,759
TrulicityDulaglutide50$56,925
MyrbetriqMirabegron53$34,376
XareltoRivaroxaban16$27,067
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$22,206
JanuviaSitagliptin Phosphate20$18,095
GemtesaVibegron25$15,975
MounjaroTirzepatide12$14,629
Repatha SureclickEvolocumab25$13,545
Praluent PenAlirocumab23$11,588
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen370$11,551
RestasisCyclosporine11$9,844
Atorvastatin Calcium1,139$9,696

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$15$182,879168 claims
GSKTrelegy Ellipta, Breo Ellipta$30$27,86739 claims
AbbVieRestasis, Synthroid$39$16,29377 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 705 internal medicine providers in Kansas.

Other internal medicine in Shawnee

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →